PULIKE issued a profit forecast, expecting a year-on-year increase of 44.70% to 64.98% in net profit attributable to the parent company in the first half of the year
PULIKE expects that the net profit attributable to the parent company in the first half of 2025 will increase by 44.70% to 64.98% year-on-year, reaching between 107 million and 122 million yuan. The launch of new products such as the live vaccine for pseudorabies in pigs and the adenovirus series five-in-one vaccine for poultry has driven performance growth, and sales of pet-related products continue to grow rapidly. The company optimizes costs and strengthens sales expense control through marketing system reform and lean production management to ensure the achievement of sales targets
According to the Zhitong Finance APP, PULIKE (603566.SH) announced that the company expects to achieve a net profit attributable to the parent company's owners of between 107 million and 122 million yuan in the first half of 2025, an increase of 44.70% to 64.98% year-on-year.
In the first half of the year, the launch of new products such as the live vaccine for pseudorabies in pigs (HN1201-R1 strain) and the adenovirus series five-in-one vaccine for poultry contributed new performance growth points for the company, while sales revenue from pet-related products continued to maintain a high growth trend. In the face of intense market competition, the company focused on transforming its marketing system, strengthening process management, and rigorously implementing performance measures to effectively ensure the achievement of sales targets. During the reporting period, the company optimized unit costs through lean production management while strengthening control over sales expenses, effectively achieving the operational goal of high-quality and high-efficiency development
